| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
MAO-B 0.023 μM (IC50)
(E)-CHBO4 specifically targets the human monoamine oxidase B (hMAO-B) enzyme. It exhibits high selectivity for the B isoform over MAO-A, thereby reducing the risk of "cheese effect" (hypertensive crisis). Its mechanism is reversible and competitive, meaning it binds to the active site of MAO-B without forming a permanent covalent bond . |
|---|---|
| ln Vitro |
(E)-CHBO4 demonstrates exceptionally potent inhibitory activity against hMAO-B with an IC50 of 0.023 uM (23 nM) . It displays a high selectivity index (SI = IC50 MAO-A / IC50 MAO-B) of approximately 1290.3. The inhibition constant (Ki) is 0.010 +/- 0.005 uM, indicating strong binding affinity to the enzyme's active site .
|
| ln Vivo |
Specific in vivo animal model data for (E)-CHBO4 is limited in the provided references. However, as a potent MAO-B inhibitor, it is expected to increase striatal dopamine levels, reduce oxidative stress, and exhibit neuroprotective effects in standard models like MPTP- or 6-OHDA-induced Parkinson's disease in rodents. Similar MAO-B inhibitors show improved motor coordination in behavioral tests .
|
| Enzyme Assay |
Enzyme activity is measured using a peroxidase-coupled spectrophotometric assay with benzylamine as a substrate. Recombinant human MAO-B enzymes are incubated with varying concentrations of (E)-CHBO4. Following incubation, the production of hydrogen peroxide (H2O2) is detected via a colorimetric reaction. The IC50 is determined by comparing activity against control wells without inhibitor .
|
| Cell Assay |
No specific cell-based assay data for (E)-CHBO4 is available in the provided references. A standard protocol for MAO-B inhibitors involves using SH-SY5Y neuroblastoma cells. Cells are pre-incubated with (E)-CHBO4 for 1-2 hours, followed by exposure to 6-hydroxydopamine (6-OHDA) or MPP+ to induce neurotoxicity. Cell viability is measured 24-48 hours later using MTT assays .
|
| Animal Protocol |
Specific in vivo protocols for (E)-CHBO4 are unavailable. A general protocol for MAO-B inhibitors in Parkinson's disease models includes dosing male C57BL/6 mice with MPTP (30 mg/kg, i.p., once daily for 5 days). (E)-CHBO4 is administered orally or intraperitoneally (e.g., 1-10 mg/kg) daily for 7-14 days. Endpoints include striatal dopamine levels via HPLC and rotarod tests for motor coordination .
|
| ADME/Pharmacokinetics |
Specific PK data for (E)-CHBO4 is unavailable. Based on structurally similar MAO-B inhibitors (MAO-B-IN-5), it is expected to have moderate oral bioavailability (e.g., ~16-30%). In rodent models, similar compounds show a T1/2 of 0.37 to 1.27 hours, Cmax of ~160-800 ng/mL, and clearance of approximately 47.1 mL/min/kg. DMSO is often used as a stock solvent for formulation .
|
| Toxicity/Toxicokinetics |
Specific toxicological data for (E)-CHBO4 is not available. The safety profile of MAO-B inhibitors generally includes gastrointestinal issues (nausea) and insomnia. Unlike non-selective MAO inhibitors, selective MAO-B agents like (E)-CHBO4 have a low risk of tyramine-induced hypertension (cheese effect). Long-term safety is extrapolated from drugs like safinamide and rasagiline .
|
| References | |
| Additional Infomation |
(E)-CHBO4 (purity ~97.04%) is a research chemical not approved for clinical use . Its structure features a para-F and para-Br substitution pattern crucial for potency. It also reduces intracellular reactive oxygen species (ROS) in Vero cells. While (E)-CHBO4 refers to the trans-isomer (CAS 126473-61-8), CHBO4 (CAS 98991-32-3) refers to the same core structure, often used interchangeably in literature .
|
| Molecular Formula |
C15H10BRFO
|
|---|---|
| Molecular Weight |
305.14
|
| CAS # |
126473-61-8
|
| Appearance |
White to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~163.86 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2772 mL | 16.3859 mL | 32.7718 mL | |
| 5 mM | 0.6554 mL | 3.2772 mL | 6.5544 mL | |
| 10 mM | 0.3277 mL | 1.6386 mL | 3.2772 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
